TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Organ-sparing With TraceIT® for Rectal Cancer Radiotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* WHO (World Health Organization) performance status 0-1 at registration~* Locally advanced (T1-2 node positive or T3 N0/N+) histologically proven rectal adenocarcinoma located in the middle or in the high rectum. Patients with tumors located in the lower rectum may be eligible if the location of the tumor do not preclude the implant of the spacer (i.e. tumors located anteriorly in the proximity of the anal sphincter)~* Indication for preoperative radiotherapy or radio-chemotherapy~* Absence of any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial~* Before patient registration/randomization, written informed consent must be given according to GCP/ICH (Guideline for Good Clinical Practice/Harmonised Tripartite Guideline), and national/local regulations.~Exclusion Criteria:~* Patient \<18 years old~* WHO performance status ≥ 2 at registration~* Patient with a local extension, clinical stage T4 and/or presenting a vagina/prostate/bladder invasion~* Active bleeding disorder or clinically significant coagulopathy (PTT \>35sec/ or INR \>1.4 (INR, international normalized ratio). Or platelet count \< 100'000/mm3)~* Active inflammatory or infectious process involving the perineum, gastrointestinal or urinary tract~* Compromised immune system (e.g. HIV/acquired immunodeficiency syndrome, autoimmune disease or immunosuppressive therapy)~* History of previous pelvic surgery~* History of active inflammatory bowel disease (Crohn's disease, ulcerative colitis, irritable bowel disease)~* Contraindication for MRI~* Pregnant or lactating females~* Inability to provide a written informed consent~* Inability to comply with study and follow up procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Recombinant Non-immunogenic Staphylokinase vs Placebo in Patients With COVID-19 - FORRIF Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women aged 18 and over~* Clinical status according to the WHO scale - 6, 7, 8 and 9 points.~* Verified respiratory infection COVID-19 by real-time PCR (quantitative)~* Patient consent to use reliable contraceptive methods throughout the study and for 3 weeks after:~  * women who have a negative pregnancy test and use the following contraceptives: intrauterine devices, oral contraceptives, contraceptive patch, prolonged injectable contraceptives, double barrier method of contraception. Women who are not fertile can also take part in the study (documented conditions: hysterectomy, tubal ligation, infertility, menopause for more than 1 year);~ * men using barrier contraception. The study may also involve men who are not fertile (documented conditions: vasectomy, infertility)~* Availability of signed and dated informed consent of the patient to participate in the study.~Exclusion Criteria:~* Clinical status according to the WHO scale - 1, 2, 3, 4 and 5 points.~* Increased risk of bleeding:~  * extensive bleeding at the present time;~ * intracranial (including subarachnoid) hemorrhage at the present time.~* Lactation, pregnancy~* Known hypersensitivity to Fortelyzin®.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: EXPERIMENTAL): Recombinant nonimmunogenic staphylokinase lyophilisate for preparation of a solution for inhaled administration, 5 mg (745,000 IU) complete with a solvent. 15 mg (2,235,000 IU) - 3 vials, regardless of body weight.
- Placebo control (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Acetyl-L-carnitine in Combination With a Cisplatin-containing Chemotherapy as First Line Treatment of Advanced or Metastatic Non Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 18~* No previous CHT or targeted therapies. Previous adjuvant or neo-adjuvant treatment is permitted if completed ≥ 6 months before study inclusion.~* ECOG performance status 0-1~* Adequate organ functions defined as follows:~* Neutrophils ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, and hemoglobin ≥ 9 g/dL~* Bilirubin level either normal or \< 1.5 x ULN~* ASAT and ALAT \< 2.5 x ULN (\< 5 x ULN if liver metastasis are present)~* Serum creatinine \<1.5 x ULN~* Written informed consent given before the randomization, according to International Conference on Harmonization/Good Clinical Practice (ICH/GCP)~Exclusion Criteria:~* Symptomatic brain metastases~* Any investigational agent(s) within 4 weeks prior to study entry~* Clinically relevant coronary artery disease or a history of a myocardial infarction within the last 12 months~* Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease~* Patients with known allergy to any other components of the study drugs~* History or presence of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or patient at high risk from treatment complication~* Known drug abuse/ alcohol abuse~* Legal incapacity or limited legal capacity~* Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent~* Clinically relevant peripheral neuropathy~* Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of the cervix (Patients with a previous malignancy but without evidence of disease for \< 5 years will be allowed to enter the trial)~* Pregnancy or breast feeding. Women of childbearing potential and their parents must be willing to practice acceptable methods of birth control to prevent pregnancy~* Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CHT cisplatin containing + placebo (Type: PLACEBO_COMPARATOR): None
- CHT cisplatin containing + acetyl-L-carnitina (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Non-Invasive Direct Current Stimulation for Cognition in Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Early course psychosis:~* DSM-V diagnosis of Schizophrenia, Schizoaffective disorder, or schizophreniform disorder.~* ages 18-50 years~* on stable doses of medication for at least one month~* not taking benzodiazepines or mood stabilizers.~* Mild to severe cognitive impairment in MATRICS Consensus Cognitive Battery (composite scores \< 40)~Chronic psychosis:~Same as early course psychosis but \>5 years of antipsychotic treatment~Exclusion Criteria:~* Diagnostic and Statistical Manual-Version V (DSM-V) diagnosis of mental retardation~* significant head injury~* medical illness affecting brain function or structure~* pregnancy or postpartum (\<6 weeks after delivery or miscarriage)~* significant neurologic disorder (e.g seizure disorder)~* inability to provide informed consent~* significant color blindness that affects task performance~* Comorbidity for DSM-V substance abuse disorder within the past one month~* Temporal relation between illness onset and head injury~* Taking benzodiazepines or mood stabilizers (lithium allowed)~* Positive drug screen (excluding THC at baseline)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Active Stimulation (Type: EXPERIMENTAL): Active stimulation group will receive 20 min of 2 mA direct current stimulation.
- Sham Stimulation (Type: SHAM_COMPARATOR): This will be an active sham involving brief (15 msec) low current (0.11 mA) pulses every 550 ms.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Double-Blind Study on Adjunctive Use of PEMF in the Treatment of 5th Metatarsal Non-Union Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject has been diagnosed with a 5th metatarsal delayed or non-union.~2. Subjects with duration of a 5th metatarsal fracture for a minimum of 3 months.~3. Male or female between ages of 18 and 75 years old, inclusive~Exclusion Criteria:~1. Subject has synovial pseudarthrosis.~2. Subject has a fracture gap of larger than 5mm as measured on CT Scan.~3. Subjects with conditions associated with elevated circulatory levels of inflammatory cytokines e.g., multiple trauma.~4. If female, subject is pregnant, plans on becoming pregnant during the duration of this clinical outcomes collection study or lactating.~5. Subject has an implanted unipolar pacemaker.~6. Subjects who have previous malignant or connective tissue disorder.~7. Subjects who use medication such as steroids or anticoagulants.~8. Subjects who have an underlying osseous infection (Osteomyelitis) and/or open wound.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- EBI Bone Healing System + Surgery (Type: EXPERIMENTAL): Subject will be using the EBI Bone Healing System (active device) in conjunction with ORIF surgery of the nonunion site.
- Placebo Device + Surgery (Type: PLACEBO_COMPARATOR): Subject will be using a placebo device in conjunction with ORIF surgery of the nonunion site.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age and older~* Diagnosis of Diabetes Mellitus (per past medical history documented in the patient medical record)~* Foot osteomyelitis (distal to ankle)~* Surgical debridement (in operating room)~Exclusion Criteria:~* Absolute neutrophil count (ANC) \< 500~* Pregnant or lactating patients~* Patients with organisms resistant to oral therapy~* Internal hardware~* Definitive amputations (BKA)~* Limb ischemia \[absent pedal pulses or ankle-brachial index (ABI) \< 0.5\]

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Midfoot (Type: ACTIVE_COMPARATOR): Individuals with an infection on the midfoot are randomized to an intravenous antibacterial agent or an oral antibacterial agent.
- Hindfoot (Type: ACTIVE_COMPARATOR): Individuals with an infection on the hindfoot are randomized to an intravenous antibacterial agent or an oral antibacterial agent.
- Toe (Type: ACTIVE_COMPARATOR): Individuals with an infection on the toe are randomized to an intravenous antibacterial agent or an oral antibacterial agent.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: IL-11 in Adults With Von Willebrand Disease Undergoing Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females 18 years of age and older~* Confirmed type 1 VWD, as defined by low VWF:RCoF or low VWF:Ag and qualitatively normal VWF multimers~* A past bleeding history~* Responsive to DDAVP~* Scheduled elective major surgery or major dental surgery at MUH or PUH~* Willingness to have blood drawn~Exclusion Criteria:~* Presence of other bleeding disorders, acquired Von Willebrand disease, primary thrombocytopenia~* Use of immunomodulatory or experimental drugs, or diuretics~* Pregnant or lactating women or those unwilling to use contraception during study~* Previous cardiac disease, congestive failure, arrhythmia (e.g. atrial fibrillation, atrial flutter), hypertension, MI, stroke, or thrombosis~* Past allergic reaction to Neumega or DDAVP~* Surgery within the past 8 weeks~* Inability to comply with study protocol requirements~* Concomitant use of antiplatelet drugs, anticoagulants, dextran, aspirin or NSAIDs~* Treatment with DDAVP, cryoprecipitate, whole blood, plasma and plasma derivatives containing substantial quantities of FVIII and/or VWF within five days of study~* Past allergic reaction to Neumega or DDAVP~* Surgery within the past 8 weeks~* Inability to comply with study protocol requirements~* Concomitant use of antiplatelet drugs, anticoagulants, dextran, aspirin or NSAIDs~* Treatment with DDAVP, cryoprecipitate, whole blood, plasma and plasma derivatives containing substantial quantities of FVIII and/or VWF within five days of study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neumega (Interleukin 11, IL-11) (Type: EXPERIMENTAL): Neumega (Oprelvekin, Interleukin 11, IL-11) 25 mcg/kg subcutaneously, given for 4 days preoperatively, and on day 5 preoperatively, and for up to 2 days postoperatively

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Applied Relaxation for Vasomotor Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* postmenopausal women (at least 12 months since last menstrual bleeding occurred or in previously hysterectomised women a serum follicle-stimulating hormone (S-FSH) defined as postmenopausal level according to references at the local laboratory)~* More or equal to 7 moderate to severe hot flashes or more or equal at 50 hot flashes per week according to a two-week screening diary~* ability to understand and speak Swedish~* freely given informed consent~Exclusion Criteria:~* unstable thyroid or other metabolic disease~* treatment with hormone therapy (HT) or other complementary- or alternative treatments treatment for menopausal-related symptoms~* treatment with psychopharmacological drugs and/or sedatives d-un-treated psychiatric disease~* frequently exercising women (≥ 2h high-intensity activities/week)

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Applied Relaxation (AR) (Type: EXPERIMENTAL): None
- Untreated Control Group (CG) (Type: NO_INTERVENTION): The women assigned to CG will be told to act as an untreated control group i.e. not to use hormonal treatment, other alternative medication, natural remedies for hot flashes and even not acupuncture, mind-body therapies or intensive physical activity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: RCT for Women With a Persisting Pregnancy of Unknown Location

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Female with a persisting pregnancy of unknown location:~   1. A pregnancy of unknown location is defined as a women with a positive pregnancy test but no definitive signs of pregnancy in the uterus or adnexa on ultrasound imaging (Ultrasound must be performed within 7 days prior to randomization)~  2. Persistence of hCG is defined as 3 serial hCG values over 4-14 days or 2 serial hCG values over 7-14 days, showing less than 30% rise, or less than 30% fall between the first and last value. (This abnormal pattern of serial hCG confirms that the gestation is nonviable.)~2. Patient is hemodynamically stable, hemoglobin greater than 10 mg/dL,~3. Greater than or 18 years of age~Exclusion Criteria:~1. Hemodynamically unstable in need of acute treatment~2. Most recent hCG greater than 5000 IU/mL~3. Patient obtaining care in relation to a recently completed pregnancy (delivery, spontaneous or elective abortion),~4. Diagnosis of gestational trophoblastic disease,~5. Subject unwilling or unable to comply with study procedures,~6. Presence of clinical contraindications for treatment with methotrexate (ACOG guidelines, Appendix B),~7. Prior medical or surgical management of this gestation.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Uterine evacuation, then MTX for some (Type: ACTIVE_COMPARATOR): Subjects will undergo a uterine evacuation. If hCG levels do not sufficiently decrease after the uterine evacuation, the subject will be treated with methotrexate. If hCG levels do sufficiently decrease after the uterine evacuation, no further treatment is required.
- Empiric treatment with MTX for all (Type: ACTIVE_COMPARATOR): Subjects will be treated with methotrexate, receiving one dose on day 0 and a subsequent dose on day 4. Additional doses will be administered as needed based on hCG levels.
- Expectant Management (Type: ACTIVE_COMPARATOR): Subjects will have their PPUL expectantly managed using serum hCG monitoring.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Prucalopride Versus Placebo in Gastroparesis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Consecutive patients with a previously established diagnosis of diabetes or functional dyspepsia according to Rome III criteria, and with delayed gastric emptying (t1/2 for solids ≥ 109 min) on a breath test~Exclusion Criteria:~* The presence of oesophagitis, gastric atrophy or erosive gastroduodenal lesions on endoscopy~  * the presence of lesions on small bowel X-ray~ * major abdominal surgery~ * underlying psychiatric illness~ * use of non-steroidal anti-inflammatory drugs, steroids, or drugs affecting gastric motility.~ * Major co-morbidities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prucalopride (Type: ACTIVE_COMPARATOR): Prucalopride tablet 2 mg
- Placebo (Type: PLACEBO_COMPARATOR): matching placebo tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: HiFIT Study : Hip Fracture: Iron and Tranexamic Acid

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years,~* Osteoporotic Fractures of the upper end of the femur requiring surgical repair.~* Preoperative hemoglobin between 9.5 and 13 g/dl.~* Patient or relative signed informed consent or inclusion thanks to urgent inclusion procedure~Exclusion Criteria:~* Bone marrow disease or ongoing treatment (such as chemotherapy), which could interfere with bone marrow erythropoiesis,~* Known allergy or counter-indication to iron and/or to tranexamic acid,~* Uncontrolled arterial hypertension,~* Recent iron infusion (within one week),~* Blood transfusion within one week before inclusion or preoperative blood transfusion already scheduled,~* Any patient who cannot be transfused or has refused consent for a blood transfusion,~* Bedridden or very dependent patient (equivalent to GIR 1 or 2 class).~* Non-affiliation to French health care coverage,~* Adult patient protected under the law (guardianship),~* Pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TXA + IIM (Type: EXPERIMENTAL): The patients randomized to this arm will have iron isomaltoside 1000 and tranexamic acid
- Placebo TXA + IIM (Type: EXPERIMENTAL): The patients randomized to this arm will have iron isomaltoside 1000 and Placebos tranexamic acid
- TXA + Placebo IIM (Type: EXPERIMENTAL): The patients randomized to this arm will have Placebos iron isomaltoside 1000 and tranexamic acid
- Placebo TXA + Placebo IIM (Type: EXPERIMENTAL): The patients randomized to this arm will have Placebos iron isomaltoside 1000 and Placebos tranexamic acid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval